Literature DB >> 28857361

Modulation of VIPergic phenotype of enteric neurons by colonic biopsy supernatants from patients with inflammatory bowel diseases: Involvement of IL-6 in Crohn's disease.

F Soufflet1,2,3, M Biraud1,2,3, M Rolli-Derkinderen1,2,3, B Lardeux1,2,3, C Trang1,3,4, E Coron1,2,3,4, S Bruley des Varannes1,2,3,4, A Bourreille1,2,3,4, M Neunlist1,2,3.   

Abstract

BACKGROUND: Neuroplastic changes in the enteric nervous system (ENS) observed during IBD might participate in physiopathological processes. Vasoactive intestinal polypeptide has been shown to be involved in intestinal inflammation and barrier functions. We aimed to investigate the modulation of VIP expression in colonic biopsies of IBD patient, the ability of soluble factors from biopsies to reproduce in vitro these modulations and identify soluble factors responsible.
METHODS: VIP and cytokines mRNA expressions were assessed in colonic biopsies of healthy subjects (HS) and IBD patients from inflamed (I) and non-inflamed areas (NI). Supernatants (SUP) of biopsies were applied to primary culture of ENS and VIP and cytokines mRNA expressions were assessed. The role of cytokines in SUP induced changes in VIP expression was evaluated. KEY
RESULTS: VIP mRNA expression was lower in biopsies of patients with Crohn's disease (CD) than Ulcerative Colitis (UC) but unchanged as compared to HS. VIP mRNA and protein expression were lower in primary culture of ENS incubated with SUP-CD than with SUP-UC. Furthermore, in CD but not UC, SUP-I reduced VIP expression in the ENS as compared to SUP-NI. Next, IL-6 but not IL-5, IL-10, IL-17, IFN-γ or TNF-α reduced VIP expression in the ENS. Finally, in CD, SUP-I incubated with anti-IL-6 antibody increased VIP expression as compared to SUP-I alone. CONCLUSIONS & INFERENCES: Mucosal soluble factors from IBD induce VIP neuroplastic changes in the ENS. IL-6 was identified as a putative soluble factor responsible in part for changes in VIP expression in CD.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  enteric nervous system; inflammatory bowel disease; vaso-intestinal polypeptide

Mesh:

Substances:

Year:  2017        PMID: 28857361     DOI: 10.1111/nmo.13198

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  4 in total

1.  Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients.

Authors:  Sabine Buhner; Hannes Hahne; Kerstin Hartwig; Qin Li; Sheila Vignali; Daniela Ostertag; Chen Meng; Gabriele Hörmannsperger; Breg Braak; Christian Pehl; Thomas Frieling; Giovanni Barbara; Roberto De Giorgio; Ihsan Ekin Demir; Güralp Onur Ceyhan; Florian Zeller; Guy Boeckxstaens; Dirk Haller; Bernhard Kuster; Michael Schemann
Journal:  PLoS One       Date:  2018-03-12       Impact factor: 3.240

Review 2.  Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells.

Authors:  Xiong Sun; Yao Huang; Ya-Li Zhang; Dan Qiao; Yan-Cheng Dai
Journal:  World J Gastroenterol       Date:  2020-12-28       Impact factor: 5.742

3.  Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.

Authors:  Sarah Alrubia; Jialin Mao; Yuan Chen; Jill Barber; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2022-09-03       Impact factor: 5.577

Review 4.  Biological characteristics of IL-6 and related intestinal diseases.

Authors:  Yuexin Guo; Boya Wang; Tiantian Wang; Lei Gao; Ze-Jun Yang; Fei-Fei Wang; Hong-Wei Shang; Rongxuan Hua; Jing-Dong Xu
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.